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Stabilized HIV-1 envelope glycoproteins (Env) that resemble the native Env are utilized in
vaccination strategies aimed at inducing broadly neutralizing antibodies (bNAbs). To limit the
exposure of rare isolate-specific antigenic residues/determinants we generated a SOSIP
trimer based on a consensus sequence of all HIV-1 group M isolates (ConM). The ConM
trimer displays the epitopes of most known bNAbs and several germline bNAb precursors.
The crystal structure of the ConM trimer at 3.9 Å resolution resembles that of the native Env
trimer and its antigenic surface displays few rare residues. The ConM trimer elicits strong
NAb responses against the autologous virus in rabbits and macaques that are significantly
enhanced when it is presented on ferritin nanoparticles. The dominant NAb specificity is
directed against an epitope at or close to the trimer apex. Immunogens based on consensus
sequences might have utility in engineering vaccines against HIV-1 and other viruses.
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The enormous diversity of human immunodeficiency virus(HIV)-1 strains is a major obstacle for the development ofa broadly protective vaccine1,2. Diversity is highest in the
envelope glycoprotein complex (Env), the target for neutralizing
antibodies (NAbs), where amino acid sequences can differ by up
to 35% between subtypes. For comparison, a change of 2% at the
amino acid level in influenza hemagglutinin can render vaccine-
induced immune responses ineffective, requiring yearly updates
of the influenza vaccine1. Thus HIV-1 diversity makes it extre-
mely difficult to induce broadly reactive NAbs (bNAbs) by an Env
immunogen from any one particular HIV-1 isolate.
Moreover, even NAb responses against the sequence-matched
neutralization-resistant (Tier 2) virus are usually not induced by
gp120 or non-native Env trimers and were facilitated by the
design of stable soluble mimics of the native Env trimer, such as
BG505 SOSIP.6643–5. This prototype native-like trimer contains
an extra intermolecular disulfide bond (SOS) to link gp120 and
gp41 and a point substitution (I559P, i.e., IP) to aid assembly of
the gp41 subunits into their pre-fusion form4,6,7. High-resolution
X-ray and cryo-electron microscopic structures of BG505
SOSIP.6648 have enabled further improvement and stabilization
of BG505 SOSIP trimers and facilitated the generation of SOSIP
trimers from other HIV-1 strains and subtypes9. However, such
trimers might not be expected to represent stand-alone vac-
cines, since these immunogens predominantly induced isolate-
specific NAbs and sporadic and/or weak heterologous Tier 2 NAb
responses at best, even when used in combination or sequential
immunization regimens10,11.
Considering HIV-1’s diversity, native-like trimers of any spe-
cific viral isolate might not be the optimal platform for inducing
bNAbs. Immunogens based on consensus sequences might be
more appropriate, since a consensus sequence is usually closer to
circulating isolates than circulating isolates are to one another2.
Furthermore, rare isolate-specific antigenic residues/determinants
are “averaged away” in the consensus sequence, which might
favor more cross-reactive responses over isolate-specific respon-
ses2. However, these semi-artificial consensus sequences might
not fold into a native-like Env structure efficiently, because
important isolate-specific interactions within the trimer might be
removed in generating a consensus sequence. Recombinant non-
native Env protein immunogens based on consensus sequences
have previously been generated2,12–15. However, such non-native
immunogens are unlikely to induce NAbs against quaternary
structure-dependent epitopes that are only present on the native
trimer including, but not limited to, ones that target the
trimer apex.
Here we describe the generation, crystal structure, and
immunogenic properties of a native-like Env (SOSIP) trimer
based on a group M consensus sequence. The ConM SOSIP tri-
mer induces NAbs against the autologous Tier 1A virus and
related Tier 1B ConS virus. In addition, these responses target the
trimer apex and are enhanced when the trimers are presented on
nanoparticles. This study shows that native-like HIV-1 Env tri-
mers can be generated from consensus sequences and such
immunogens might be suitable vaccine components to prime
and/or boost desirable NAb responses.
Results
A group M consensus Env sequence yields native-like trimers.
We selected the last published group M consensus sequence
(from 2004; www.hiv.lanl.gov; alignment ID: 104CP2; Fig. 1a;
Supplementary Fig. 1), which is a consensus of the consensus
sequences of each clade in group M, from hereon termed ConM.
We first generated a construct based on the SOSIP.v4.2 design
(Fig. 1b)16, but to improve the quality, stability, and yield of
ConM SOSIP.v4.2, we added a second intermolecular disulfide
bond between residues 73 in gp120 and 561 in gp41 (SOSIP.v5.2)
5 and a number of amino acid changes in the trimer interface
derived from the BG505 sequence, collectively termed TD817. We
named the construct that incorporated all of these changes ConM
SOSIP.v7 (Fig. 1b, Supplementary Table 1). The interprotomer
disulfide bond included in the SOSIP.v6 design was not incor-
porated because of its adverse effects on trimer yields5.
Initial screening of unpurified ConM SOSIP.v4.2, SOSIP.v5.2,
and SOSIP.v7 proteins from transiently transfected 293T cell
supernatants showed that all constructs produced trimers, but the
SOSIP.v7 construct yielded higher-quality trimers as demon-
strated by more efficient binding of quaternary-dependent bNAbs
PG16, PGT145, PGT151, and 35O22 in an enzyme-linked
immunosorbent assay (ELISA; Supplementary Fig. 2a, b). The
ConM SOSIP.v7 construct also resulted in higher trimer yields
(~4.9 mg/L) than SOSIP.v4.2 (~0.9 mg/L) and SOSIP.v5.2 (~0.9
mg/L) when purified by affinity chromatography using trimer-
specific PGT145 bNAb (Table 1). Similarly, when the ConM
proteins were purified from transiently transfected 293S cells by
2G12-affinity chromatography followed by size exclusion chro-
matography (SEC), the SOSIP.v7 construct resulted in higher
trimer yields (77% trimers, ~1.0 mg/L) compared to SOSIP.v4.2
(35%, ~0.2 mg/L) and SOSIP.v5.2 (65%, ~0.7 mg/L) (Fig. 1c).
All purified ConM SOSIP trimer versions were completely
cleaved (Supplementary Fig. 2c), but ConM SOSIP.v7 interacted
more efficiently with quaternary structure-dependent bNAbs
PG16, PGT145, PGT151, and 35O22 and showed decreased
binding to undesirable V3-directed non-NAb 19b (Supplemen-
tary Fig. 2d). Negative-stain electron microscopy (NS-EM)
revealed that ~100% of the ConM SOSIP.v7 trimers had a
native-like morphology (Fig. 1d, Table 1). Differential scanning
calorimetry (DSC) analyses showed that ConM SOSIP.v7
displayed high thermostability that was comparable to BG505
SOSIP.664 (midpoint of thermal denaturation (Tm)= 67.8 °C and
68.1 °C, respectively) (Fig. 1e, Table 1)4. Moreover, the majority
of the glycans on ConM SOSIP.v7 trimers are oligomannose
(68%), in particular Man9GlcNAc2 (25%) and Man8GlcNAc2
(12%) (Fig. 1f, Table 1), which very closely matches other soluble
native-like Env trimers18–22, and is consistent with the strong
binding of glycan-dependent bNAbs (see above and below).
By all the evaluated criteria, we conclude that the ConM
SOSIP.v7 construct produced high-quality, native-like trimers
that can be purified at high yield in different expression systems,
across different laboratories, and using different purification
methods.
ConM SOSIP.v7 engages germline precursors of V2-apex
bNAbs. Env immunogens that interact with bNAbs do not
necessarily bind the germline precursors of these bNAbs, in
which case they are unlikely to induce similar bNAbs by vacci-
nation23–27. We tested the ability of ConM SOSIP.v7 trimers to
bind to the inferred germline precursors of several bNAbs (gl-
bNAbs) in a Ni-NTA His-capture ELISA, focusing on V2-apex
bNAbs. As comparators, we used the BG505 SOSIP.v5.2 trimer
and the BG505 GT1.1 trimer, an updated germline-targeting
immunogen derived from the BG505 GT1 trimer that was spe-
cifically engineered to engage VRC01-class gl-bNAbs and
enhance binding to V2-apex gl-bNAbs28,29.
The BG505 SOSIP.v5.2 trimer interacted well with gl-PG9 and
gl-CH01 and also weakly with gl-PG16, consistent with previous
observations using BG505 SOSIP.664 (Fig. 1g; ref. 24); however,
the GT1.1 trimer bound more strongly to gl-PG9, gl-PG16, and
gl-CH01 than its BG505 SOSIP precursor, as reported previously
(Fig. 1g; ref. 29). The ConM SOSIP.v7 trimer engaged gl-PG9 and
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gl-PG16 with higher affinity compared to the BG505 SOSIP.v5.2
trimer but not as strongly as the GT1.1 trimer. Furthermore, the
ConM SOSIP.v7 trimer was able to engage gl-CH01, albeit with
lower affinity compared to the other two trimers. Only the
engineered GT1.1 trimer interacted with the VRC01-class bNAb
gl-PGV19 (Fig. 1g). We conclude that, even without specific
germline-targeting modifications, the ConM SOSIP.v7 trimer was
able to engage the inferred germline precursors of several V2-
apex bNAbs.
ConM SOSIP.v7 is structurally similar to other Env trimers.
Native-like trimers from HIV-1 clades A, B, C, and G have been
characterized extensively by biochemical and structural
approaches30–36, and recently, an Env trimer based on the con-
sensus sequence of several clade C Env sequences was descri-
bed37. A high-resolution structure would inform future structure-
based design efforts that use ConM SOSIP.v7 as the platform.
Therefore, we determined the crystal structure of ConM SOSIP.v7
in complex with bNAbs PGT124 and 35O22 at 3.9 Å resolution
by molecular replacement (MR) method using the crystal struc-
ture of BG505 SOSIP.664 in complex with Fabs 3H+109L and
35O22 (PDB ID: 5CEZ) as a MR phasing model32 (Fig. 2a,
Table 2).
Overall, the ConM SOSIP.v7 trimer has high structural
similarity with trimers from clade A (BG505 SOSIP.664), clade
C (16055 NFL TD CC), and clade G (X1193.c1 SOSIP.664), as
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from which the cytoplasmic tail was removed (ΔCT)), with Cα
root mean square deviations of 0.80 Å, 0.60 Å, 0.79 Å, and 1.05 Å,
respectively (Fig. 2b)30–32,34–36. The overall structural similarity
confirms that the ConM SOSIP.v7 trimer, based on a consensus
sequence, mimics the native Env trimer conformation. Interac-
tions between ConM SOSIP.v7 and bNAbs PGT124 and 35O22
are similar to those reported for other trimers in that PGT124
recognizes the N332 glycan and the 324GDIR327 motif at the V3
loop base and 35O22 interacts at the gp120/gp41 interface
(Supplementary Fig. 3a, b)34–36,38–40. All of the TD8 residues
(E47D, N49E, V65K, E106T, I165L, G429R, Q432, and K500R)
could be resolved in our crystal structure and their side chains
were similarly oriented as in the clade A BG505
SOSIP.664 structure (PDB ID: 5CEZ, Supplementary Fig. 4a).
The intersubunit C73-C561 disulfide bond could not be
confirmed in the structure because the region around residue
C561 lacked interpretable electron density. On each ConM
SOSIP.v7 monomer, 49 glycan saccharide residues of glycans at
16 of the 30 predicted that Asn-X-Ser/Thr sequons had
interpretable electron density (Supplementary Table 2 and
Supplementary Fig. 4b)41.
ConM SOSIP.v7 displays few rare antigenic determinants. To
further study the antigenic surface of the ConM SOSIP.v7 trimer,
we analyzed the conservation of each residue among all the HIV-
1 envelope glycoprotein sequences (n= 6112) available from the
Los Alamos HIV database (http://www.hiv.lanl.gov/), as present
in 2017. When we compared amino acid conservation of each
equipositional residue of ConM and BG505, 65 residues exhibit
differences in the amino acid conservation. ConM contains 14
residues that are rarer than equipositional residues of BG505
while BG505 contains 51 rarer residues. Considering the trimeric
assembly of Env proteins, the ConM trimer would contain many
fewer rarer residues than the BG505 trimer (Fig. 2c and Sup-
plementary Table 3). Furthermore, analysis of the ConM env
sequence using the Glycan Shield Mapping tool42 showed that
ConM does not lack potential N-linked glycosylation sites that
might cause holes in the glycan shield, in contrast to the protypic
BG505 env sequence (Fig. 2d).
Together, these data imply that the ConM trimer displays
considerably less rare antigenic residues/determinants compared
with the BG505 trimer, a property that might facilitate the
induction of cross-reactive NAbs.
ConM SOSIP.v7 nanoparticles activate cognate B cells. Parti-
culate display of antigens can improve immunogenicity by
enhancing B cell receptor (BCR) cross-linking and B cell activa-
tion43. Indeed, the immunogenicity of BG505 SOSIP.664 trimers
can be enhanced by presenting them on ferritin nanoparticles
displaying eight trimers per particle44. Therefore, we genetically
Fig. 1 Design, screening, and biophysical characterization of ConM SOSIP trimers. a Maximum likelihood tree generated with all Env sequences of the M
group from the Los Alamos HIV database webalignment 2011 (n= 3654) and the parental Env sequences of five previously described SOSIP
trimers4, 17, 72, 81 and ConM. Different subtypes and genetic distance bar (substitutions per sequence position) are indicated. b Linear representation of the
three ConM SOSIP variants. Top: design of SOSIP.v4.2 with the SOS-bond (A501C-T605C), improved furin cleavage site (R6), IP (I559P), trimer-stabilizing
mutations (H66R and A316W), and improved trimerization mutations (I535M and Q543N)4, 16. Middle: design of SOSIP.v5.2 with an extra intermolecular
disulfide bond (A73C-A561C)5. Bottom: design of SOSIP.v7 with TD8 mutations in blue17. The assignment of glycans was based on the analysis of BG505
SOSIP.664 reported in ref. 41 but may be different for ConM SOSIP trimers. c Size exclusion chromatographic profiles of 2G12-purified ConM SOSIP trimers
(untagged) expressed in 293S cells on a Superdex200 16/60 column. d 2D class average of negative-stain electron microscopic analyses of PGT145-
purified ConM SOSIP.v7 trimer (D7324-tagged) expressed in 293F cells. Percentages of closed and open native-like are depicted in green and non-native in
red. e Thermostability derived from differential scanning calorimetry (DSC) of PGT145-purified ConM SOSIP.v7 trimer (D7324-tagged) expressed in 293F
cells. The DSC parameters midpoint of thermal transition (Tm), starting temperature of unfolding (Tonset), and width of the transition at half peak height (T1/
2) are indicated. f Hydrophilic interaction liquid chromatography-ultra performance liquid chromatographic spectra of N-linked glycans derived from
PGT145-purified ConM SOSIP.v7 trimer (D7324-tagged) in 293F cells. Peaks corresponding to oligomannose glycans (Man5–9GlcNac2) are labeled
M5–M9. The smaller peaks that are not highlighted correspond to complex or hybrid-type glycans. The relative abundances of M5–M9 and complex
glycans are summarized in a circle diagram. g Ni-NTA-capture enzyme-linked immunosorbent assay with PGT145-purified ConM SOSIP.v7 trimer and the
comparator trimers BG505 SOSIP.v5.2 and GT1.1 (all His-tagged) expressed in 293F cells against a panel of (gl-)bNAbs
Table 1 Biophysical characterization of stabilized ConM SOSIP trimers
SOSIP versiona v4.2 v5.2 v7 v7-ferritin
Production Yield (mg/L)b 0.9c 0.9c 4.9c 3.5
Yield (mg/L)d 0.2e 0.7e 1.0e ND
Morphology NS-EMb Native-like trimers (%) ND ND ~100c ND
Closed native-like trimers (%) ND ND ~45c ND
DLSb Rh (nm) ND ND 6.4c 13.4
Pd (%) ND ND 12.5c 59.9
Thermostabilityf DSCb Tm (°C) 65.1c ND 67.8c 72.0
DSCd Tm (°C) 65.6e 68.8e 66.7e ND
Glycan composition HILIC-UPLCb Man8 (%) 21c ND 12c 20
Man9 (%) 23c ND 25c 24
Oligomannose (%) 75c ND 68c 75
DLS dynamic light scattering, DSC differential scanning calorimetry, HILIC-UPLC hydrophilic interaction liquid chromatography-ultra performance liquid chromatography, ND not determined, NS-EM
negative-stain electron microscopy
aA linear representation and an overview of the modifications made to the trimer variants is shown in Figs. 1b and 2a and Supplementary Table 1
bData were derived from 293F cell-expressed and PGT145-purified SOSIP trimers
cData were derived from SOSIP trimers containing a D7324-tag
dData were derived from 293S cell-expressed and 2G12/SEC-purified SOSIP trimers
eData were derived from SOSIP trimers without a tag
fTm values that were obtained with D7324-tagged SOSIP trimers were up to 0.3 °C higher than those without a tag
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fused ConM SOSIP.v7 to Helicobacter pylori ferritin (Fig. 3a) and
purified these nanoparticles by PGT145 purification from the
supernatant of transiently transfected 293F cells (yield of ~3.5
mg/L) (Table 1). ELISA showed that the ferritin scaffold did not
dramatically change the antigenicity of ConM SOSIP.v7 trimers,
since most bNAbs (2G12, VRC01, PGT121, PGT135, and PG16)
interacted with the ConM trimers on the nanoparticles (Supple-
mentary Fig. 5a) and these data were corroborated by biolayer
interferometry (BLI) experiments (Supplementary Fig. 6). How-
ever, a minority of the ConM SOSIP.v7-ferritin material was
uncleaved at the gp120/gp41 junction, despite the use of increased
amounts of furin (see “Methods” ; Supplementary Fig. 5b).
Similar observations were also made with ferritin nanoparticles
displaying SOSIP trimers from other isolates44,45. Thus furin
access to its substrate cleavage site appears to be hindered to some
extent when Env trimers are presented on ferritin particles.
Negative stain-EM showed that ConM SOSIP.v7-ferritin
formed particles with a diameter of 30–40 nm consisting of a
spherical ferritin core from which eight trimer spikes protruded,
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Fig. 2 The consensus sequence-based ConM SOSIP.v7 trimer shares structural similarity to other Env structures. a Crystal structure of ConM SOSIP.v7
trimer (gp120 green, gp41 blue) in complex with Fabs PGT124 (cyan) and 35O22 (orange) at 3.9 Å resolution. For clarity, two other ConM SOSIP.v7
protomers are represented as white surface and mesh. b Superimposition of the soluble ConM SOSIP.v7 monomer (gp120 green, gp41 blue), clade A
BG505 SOSIP.664 (PDB: 5CEZ), clade B JRFL Env ΔCT (PDB: 5FUU), clade C 16055 NFL TD CC (PDB: 5UM8), and clade G X1193.c1 SOSIP.664 (PDB:
5FYJ). c Comparison of rarer amino acid residues of ConM and BG505. After analyzing amino acid conservation for each residue among all the HIV-1
envelope glycoprotein sequences (n= 6112) available from the Los Alamos HIV database 2017, amino acid residues in ConM and BG505 that are rarer
than equipositional residues in BG505 and ConM, respectively, are represented in red. There are 14 and 51 rarer residues in each ConM and BG505
protomer, respectively. d Visualization of the glycan shield of ConM Env, containing no glycan holes (top), and the prototypic BG505 Env, which contains
the 241/289 glycan hole (bottom). Glycan shields were modeled using the Glycan Shield Mapping tool42
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the raw micrographs (Fig. 3b and Supplementary Fig. 5c). The
glycan composition of the ferritin-presented ConM SOSIP.v7
trimers was similar to that of the soluble trimers (Fig. 3c, Table 1)
and the dynamic light scattering (DLS) analyses confirmed the
dimensions that were observed in NS-EM with a hydrodynamic
radius (Rh) of 13.4 nm for ConM SOSIP.v7-ferritin and 6.4 nm
for single ConM SOSIP.v7 trimers (Fig. 3d, Table 1). The
polydispersity was relatively high (>15%)46, consistent with the
presence of incompletely formed particles. The ConM SOSIP.v7-
ferritin particle displayed an increased thermostability compared
to free ConM SOSIP.v7 trimers (Tm= 72.0 °C versus Tm= 67.8 °
C, respectively), but the melting peak of the nanoparticles was
slightly broader than that of the trimer only (T1/2= 6.3 °C versus
T1/2= 5.5 °C), because of the concurrent melting of the ferritin
nanoparticle and/or because of the heterogeneity among the
trimers on the ferritin nanoparticles (Fig. 3e, Table 1).
We also addressed the thermostability of antigenic determi-
nants. Accordingly, we incubated ConM trimers and ConM
trimers on ferritin nanoparticles for an hour at 4 °C (negative
control), 37 °C (mimicking vaccination), and at 60 °C, 68 °C, and
72 °C (mirroring the unfolding events in the DSC profile), prior
to antigenicity analysis using BLI (Fig. 3f, Supplementary Fig. 6).
Single ConM SOSIP.v7 trimers interacted efficiently with the
quaternary-specific bNAb PGT145, but the binding signal was
reduced after incubation at 60 °C (Tonset), consistent with
initiation of unfolding and the dissociation of trimer interactions,
and was abrogated after incubation at 68 °C or 72 °C. The reverse
result was obtained with 19b for which the binding steadily
increased with temperature, consistent with exposure of its linear
epitope upon protein unfolding. F105 binding was increased after
incubation at 60 °C, consistent with trimer dissociation, but
decreased after incubation at 68 °C or 72 °C, in line with loss of
gp120 integrity.
The nanoparticle-displayed ConM SOSIP.v7 trimers showed
enhanced binding to 2G12 and PGT145 bNAbs compared to the
soluble trimers at 4 °C and 37 °C, probably due to increased
avidity of the nanoparticle-displayed epitopes (Fig. 3f). At 60 °C
(Tonset) and 68 °C (Tm of ConM SOSIP.v7), PGT145 binding was
(mostly) retained for ConM SOSIP.v7-ferritin, while it was
strongly decreased for the soluble trimers (Fig. 3f). This implies
that the ferritin moiety provides additional conformational
stability to the ConM SOSIP.v7 trimers.
The ConM nanoparticles also interacted efficiently with the
19b and F105 non-NAbs at 4 °C and 37 °C, while the soluble
trimers only did so at increased temperatures (>60 °C, Fig. 3f).
The display of non-NAb epitopes implies that the ferritin
nanoparticles also harbor non-native Env trimers, consistent
with the presence of uncleaved ConM gp140 observed in sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
analysis (Supplementary Fig. 5b) and the broader melting peak
for ConM SOSIP.v7-ferritin nanoparticles compared to free
ConM SOSIP.v7 trimers (Fig. 3e).
Next, we assessed whether presentation of ConM SOSIP.v7
trimers on ferritin nanoparticles provided an advantage in
activation of B cells. B cell lines that can be induced to express
bNAbs VRC01, PGT145, PGT121, or PG16 as their BCR47 were
incubated with soluble trimers or trimers presented on ferritin
nanoparticles and the calcium flux upon encounter with antigen
was measured by fluorescence-activated cell sorting analysis. At a
concentration of 50 nM, the soluble trimers were able to weakly
activate B cells expressing PGT121 and PG16 BCRs but were
inactive against those expressing VRC01 and PGT145. In
contrast, at the same molar amount of trimers (6.25 nM of
nanoparticles), the ConM SOSIP.v7-ferritin nanoparticles acti-
vated all four B cells efficiently (Fig. 3g). These data imply that
particulate presentation of ConM SOSIP.v7 trimers enhances
their capability to activate cognate B cells.
Immunogenicity of ConM SOSIP.v7 in rabbits. To test the
immunogenicity of ConM SOSIP.v7 trimers and ferritin nano-
particles, we vaccinated rabbits three times at weeks 0, 4, and 20
with 22 µg (Env protein equivalent) of either soluble ConM SOSIP.
v7 trimers (n= 5) or ConM SOSIP.v7-ferritin nanoparticles (n=
5), formulated in ISCOMATRIX™ adjuvant (Fig. 4a)3.
After two immunizations, all rabbits developed strong binding
Ab responses against the corresponding ConM SOSIP.v7 trimer
that waned but were boosted again by the third immunization
(Fig. 4b). Four weeks after the prime, the binding Ab responses
were seven-fold higher in the ConM SOSIP.v7-ferritin group
compared to the single trimer (p= 0.0159), but these differences
were less prominent (two-fold, p= 0.0079 at week 12) or non-
significant (weeks 6, 20, and 22) after subsequent boosting
immunizations (Fig. 4b).
To assess the induction of autologous NAb responses, we
constructed an infectious molecular clone (IMC) containing the
autologous ConM Env. This clone produced infectious virus at
high titers that infected TZM-bl cells. Analysis of the sensitivity to
a panel of bNAbs, non-NAbs, and reference serum pools revealed
that the ConM virus was a highly neutralization-sensitive (Tier
1A) virus. However, the ConM virus was not sensitive to V3-
directed non-NAbs, which is atypical for a Tier 1A virus
(Supplementary Table 4)48.
The autologous NAb responses mirrored the binding Ab
responses (Fig. 4c). Thus, after two immunizations, all rabbits
Table 2 Data collection and refinement statistics





a, b, c (Å) 127.59, 127.59, 315.51
α, β, γ (°) 90, 90, 120
Resolution (Å) 50.0–3.90 (4.04–3.90)a
Observations 412,746
Unique reflections 23.583 (1613)
Rsym 0.15 (1.07)
I / σI 15.7 (1.0)
CC1/2 0.95 (0.70)



















Bond lengths (Å) 0.007
Bond angles (°) 1.312
aValues in parentheses are for the highest-resolution shell
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developed strong autologous NAb responses against the
corresponding ConM virus that waned and were boosted by
the third immunization. The autologous NAb responses were
significantly higher in the ConM SOSIP.v7-ferritin group
compared to the single trimer group at week 4 (three-fold
difference, p= 0.0159), week 6 (two-fold, p= 0.0159), and week
20 (four-fold, p= 0.0159) but not at week 22 (Fig. 4c).
Furthermore, the ConM SOSIP.v7-binding Ab titers correlated
strongly with the autologous ConM NAb titers (Spearman r=
0.88, p < 0.0001; Fig. 4d).
We also tested neutralization against the related but more
resistant ConS pseudovirus. The ConS virus was categorized as a
Tier 1B virus, albeit at the resistant end of the Tier 1B spectrum.
The ConS virus was completely resistant to most Abs that
typically neutralize Tier 1 viruses, such as F105 and 447–52D
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Fig. 3 Design and characterization of ConM SOSIP-ferritin nanoparticles. a Left: linear representation of ConM SOSIP.v7-ferritin. The N-terminus from H.
pylori ferritin (purple) is linked to the SOSIP.v7 C-terminus by a Gly-Ser-Gly (GSG) linker. Right: model of eight ConM SOSIP.v7 trimers with gp120 subunits
(red) and gp41 subunits (pink), displayed on the H. pylori ferritin nanoparticle (purple, PDB: 3BVE) viewed down the two-fold, three-fold, and four-fold axis
of the ferritin particle, respectively. The figure was drawn using PyMol. b The two-dimensional class averages of the negative-stain electron microscopic
analyses of ConM SOSIP.v7-ferritin nanoparticle. Example images of the micrographs are shown in Supplementary Fig. 5c. c Representative dynamic light
scattering graphs showing the size distribution of ConM SOSIP.v7 trimer and SOSIP.v7-ferritin nanoparticle. d Glycan profile of the ConM SOSIP.v7-ferritin
nanoparticle as determined by hydrophilic interaction liquid chromatography-ultra performance liquid chromatography. The circle diagram indicates the
relative amounts of Man5–9GlcNac2 (M5–M9) and complex glycans. e Thermostability (measured by differential scanning calorimetry) of PGT145-purified
ConM SOSIP.v7-ferritin nanoparticle expressed in 293F cells. The ConM SOSIP.v7 trimer melting curve (Fig. 1e) is shown in red for comparison. f Binding of
broadly neutralizing antibodies (bNAbs) 2G12 and PGT145 and non-neutralizing antibodies (non-NAbs) F105 and 19b to ConM SOSIP.v7 trimer and SOSIP.
v7-ferritin (100 nM SOSIP.v7 equivalent each) measured by biolayer interferometry after incubation at different temperatures. Shown are the mean values
of the area under the curve (AUC) derived from the binding curves in Supplementary Fig. 6. g Calcium flux (relative fluorescence) in B cells expressing
either VRC01, PGT145, PGT121, or PG16 as the B cell receptor, stimulated with ConM SOSIP.v7 trimers or ConM SOSIP.v7-ferritin nanoparticles
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consensus sequences from 2004 (i.e., the last year consensus
sequences were reported at the Los Alamos website), while ConS
is based on a consensus sequence from 2001 and has longer
variable loops12. In total, the ConM Env is 23 amino acids shorter
than ConS Env with the V1, V2, V4, and V5 loops of ConM being
3, 4, 8, and 3 amino acids fewer than those of ConS, respectively.
In addition, the ConS sequence has 27 amino acid changes
compared to ConM scattered throughout the gp160 sequence
(Supplementary Fig. 1). In this analysis, we included 12 additional
week 22 rabbit sera from an independent immunization study in
which rabbits received 20 µg ConM SOSIP.v7 or ConM SOSIP.
v7-ferritin (n= 6 animals per group), also at weeks 0, 4, and 20,
but formulated in squalene emulsion (SE) as the adjuvant49.
At week 22, 21 out of 22 rabbits had developed NAb activity
(ID50 titer >40) against the ConS pseudovirus and the levels were
~22-fold higher in the nanoparticle recipient animals (median
ID50 of 1771 for the nanoparticle group versus 82 for the single
trimer group, p < 0.0001; Fig. 4e). The sera were assayed in 2–4
different laboratories and all gave similar results (Supplementary
Table 5). Thus, particulate presentation of ConM SOSIP.v7
trimers was required to induce a strong response against the
related ConS virus. Analyses of the longitudinal autologous
neutralization responses (Fig. 4c) and ConS neutralization
responses (Fig. 4e) revealed that post-immunization 1 (week 4),
post-immunization 2 (week 6 and week 20), and post-
immunization 3 (week 22) Tier 1 A ConM NAb responses
correlated with post-immunization 3 (week 22) ConS NAb
responses (Supplementary Fig. 7). The correlation was particu-
larly strong for week 6 ConM NAb responses versus the week 22
ConS NAb responses (Spearman r= 0.9167, p= 0.0013). Thus,
early Tier 1A ConM NAb responses were predictive for later
ConS NAb responses.
Heterologous NAb responses against the Tier 1A clade B virus
SF162 were weak in the trimer group, consistent with the
presence of substitutions in the SOSIP.v7 design that limit
exposure of non-neutralizing epitopes5,16,17 but stronger in the
nanoparticle group (median ID50 of 20 versus 488,
p < 0.0001) (Fig. 4e). Similarly, the Tier 1A clade C virus
MW965.26 was neutralized more efficiently by nanoparticle
recipients than by trimer-immunized animals (median ID50 of
9982 versus 116, p= 0.0079) (Supplementary Table 5). The
heterologous Tier 1A NAb activity in most nanoparticle-
immunized animals was partially depleted by the ConM V3
peptide, while the Tier 1A NAb activity for most trimer
immunized animals was barely affected (Supplementary Table 7).
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Fig. 4 Immunogenicity of ConM trimers and nanoparticles in rabbits. a Rabbit immunization schedule. Rabbits were immunized at weeks 0, 4, and 20
(black arrows) and the antibody responses were analyzed at weeks 0, 4, 6, 12, 20, and 22 (gray arrows). b Midpoint antibody-binding titers over time
against ConM SOSIP.v7 trimer as measured by D7324-capture enzyme-linked immunosorbent assay. The dotted line indicates a midpoint titer of 50, the
lower cut-off of the assay. The mean binding titers with SD (n= 5 animals) of each group are shown. Two-tailed Mann–Whitney U test was used to
determine statistical differences between groups at each time point. *p < 0.05; **p < 0.01. c Neutralization titers (ID50) over time against the infectious
autologous ConM virus as measured in the TZM-bl assay. The dotted line indicates a midpoint titer of 20, the lower cut-off of the assay. The mean
neutralization titers with SD (n= 5 animals) of each group are shown. Two-tailed Mann–Whitney U test was used to determine statistical differences
between groups at each time point. *p < 0.05. d Antibody binding titers against ConM SOSIP.v7 trimer and autologous neutralization titers were cross-
compared over all post-prime time points. The Spearman r and p values are given. e Neutralization titers (ID50) from rabbit sera samples at week 22 (from
two different immunization studies) against autologous ConM virus (DUMC and AMC), heterologous Tier 1 SF162 and MW965.26 viruses (AMC and
DUMC), and heterologous Tier 1B ConS and Tier 2 TV1.21 virus (DUMC and AMC). Neutralization data from individual animals and the different test
laboratories can be found in Supplementary Table 5. Neutralization titers of the sera from rabbits that were immunized with the same immunogens but
with a different adjuvant are indicated with or without black bordered symbols in the figure. Horizontal lines indicate the geometric mean values. A two-
tailed Mann–Whitney U test was used to compare differences; *p < 0.05; ***p < 0.001; ****p < 0.0001
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induced anti-V3 Tier 1A NAb responses in rabbits, while the Tier
1A neutralization from soluble trimer-immunized animals is
probably mediated by non-V3 specificities.
Instances of heterologous Tier 2 virus neutralization at a titer
>40 were virtually absent from the single trimer group. Such hits,
although weak and usually sporadic, were more frequent in the
nanoparticle group, but this finding was driven mostly by NAb
responses against the clade C virus TV1.21, which was not
neutralized by any sera from the single trimer recipients but by 10
out of 11 sera from the nanoparticle group (median ID50 of 20
versus 127, p < 0.0002 for the comparison; Fig. 4e; Supplementary
Table 5).
NAbs induced by ConM SOSIP.v7 target the trimer apex. To
probe the specificities of the Ab responses, we performed serum-
binding competition experiments with bNAbs3,50. The sera were
able to compete with many bNAbs for binding to the trimer
(Fig. 5a). Particularly strong competition was observed for several
bNAbs targeting the V1V2 region on the trimer apex, such as
PG9, PG16, CH01 and VRC26.25 (<40% residual binding of these
bNAbs in the presence of sera from 8 out of 10 rabbits), except for
PGT145 (Fig. 5a). Very strong competition was also detected for
gl-PG9 and gl-CH01, showing that ConM immunogens are not
only able to interact with gl-bNAbs but also induce Abs that
interact with overlapping epitopes. Moderate competition was
also observed with VRC01 and for some sera with the two anti-
V3 glycan bNAbs. The competition of V3-glycan bNAbs (e.g.,
PGT121 and PGT128) and V1V2 bNAbs (e.g., VRC26.25 and
PG9) correlated well (Fig. 5b and Supplementary Fig. 8), sug-
gesting that ConM Abs were targeting epitopes near or over-
lapping with the V3-glycan and V1V2 regions. Furthermore, we
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Fig. 5 Mapping of antibody specificities induced by the ConM SOSIP.v7 trimer in rabbits. a Enzyme-linked immunosorbent assay-based competition assay
measuring the interference of rabbit sera with the binding of known broadly neutralizing antibodies (bNAbs) to the ConM SOSIP.v7 trimer. The numbers
represent the residual bNAb binding (0–25% in red; 26–50% in orange; 51–75% in yellow; 76–100% in green) after pre-incubation of the ConM SOSIP
trimer with a 1:100 dilution of the rabbit sera. The recorded values are average values from four independent experiments. b Correlation between serum
competition with PGT128 and serum competition with PG9 and VRC26.25 as determined in Fig. 5a. The Spearman r and p values of the correlations are
given. A complete Spearman correlation matrix is shown in Supplementary Fig. 8. c Normalized residual binding of 3BC315 and 35O22 to ConM SOSIP.v7
trimer after adding sera of ConM SOSIP.v7 and ConM SOSIP.v7-ferritin immunized rabbits. Data are derived from Fig. 5a. Differences were determined by
two-tailed Mann–Whitney U test; ***p < 0.001. d ConM NAb responses in week 22 sera from rabbits immunized with ConM SOSIP.v7 trimer (5 animals) or
ConM SOSIP.v7-ferritin nanoparticle (5 animals) compared to historic control sera (week 22) from rabbits that were immunized with BG505 SOSIP.v6 (5
animals; animal ID: 1829–1833)5. Neutralization activity was assessed against BG505, SF162, and ConM viruses. Open symbols indicate when the
autologous virus was tested. A two-tailed Mann–Whitney U test was used to compare differences; *p < 0.05; ***p < 0.001. e Neutralization titers against
ConM in the presence or absence of ConM SOSIP.v7 D368R or a ConM SOSIP.v7 D368R in which the V1V2 was swapped for that of BG505. Statistical
analysis was performed using the Wilcoxon matched-pairs signed-rank test. **p < 0.01. f Conformational epitopes in the V2–V3 region of ConM SOSIP.v7
that elicit strong NAbs. Residues within the apex and N332_V3 conformational epitopes are colored in blue (K169, Y173, N301, and G324) and red (Asn160
and Asn332) with glycans represented by stick models. Interfaces that are recognized by bNAbs PG9 and PGT128 are marked with dotted lines in magenta
and orange, respectively. Neutralization curves of one rabbit serum (#1811, Supplementary Table 7) against key mutant viruses on the right. Bottom:
alignment comparing the V1V2 amino acid sequences of ConM SOSIP.v7 with that of the ConM, ConS, TV1.21, and BG505 viruses
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weaker competition with the 35O22 and 3BC315 bNAbs targeting
the gp41–gp120 interface40,51 (both bNAbs combined, p= 0.001;
Fig. 5c). This might be explained by poor accessibility of the
gp41–gp120 interface when the trimers are presented on ferritin
nanoparticles44. In contrast, soluble ConM trimers expose a
glycan-free area on their base that induces Abs that can compete
with 3BC315 and 35O2252.
Next, we attempted to determine the specificity of the NAb
response against the autologous ConM virus. The Tier 1A status
of this virus prompted us to investigate whether there was a role
for V3, despite the fact that ConM is not very sensitive to most
V3 non-NAbs (Supplementary Table 4). NAbs that target linear
V3 epitopes usually do not contribute to Tier 2 NAb responses
and are therefore not useful on the path toward a bNAb-based
vaccine3. We used a cyclic ConM V3 peptide to deplete the
autologous ConM NAbs from the sera of the ten rabbits. The V3
peptide was unable to deplete the ConM NAb responses from any
of the sera, while the ConM SOSIP.v7 D368R protein depleted
almost all neutralization activity (Supplementary Table 6).
To confirm that simple linear V3 specificities played no
significant role in autologous NAb responses, we made use of five
historic control sera from animals that were vaccinated with
BG505 SOSIP.v6 (animal IDs: 1829–1833; for the BG505 SOSIP.
v6 sequence, see Supplementary Fig. 1) and neutralized the Tier
1A virus SF162, through V3 specificities5 (Fig. 5d). ConM and
BG505 have identical V3 loop sequences, but despite the sequence
similarities in the V3 and the presence of V3-directed Tier 1A
NAbs, none of the historic control sera neutralized the ConM
virus, confirming that the autologous ConM response is not a
typical V3-directed Tier 1A NAb response.
The competition ELISA suggested the V1V2 as a major target
for binding Abs and the same Abs might also be responsible for
neutralizing the autologous virus. To investigate, we generated a
ConM SOSIP.v7 D368R protein in which the V1V2 domain was
replaced with that of BG505. This hybrid trimer was purified
using PGT145 and used in neutralization-depletion experiments.
While the parental ConM SOSIP.v7 D368R trimer depleted all
NAb activity from the sera of all ten rabbits, the hybrid trimer
with the BG505 V1V2 domain had no such effect, showing that
the ConM V1V2 domain is (part of) the dominant ConM NAb
response in all rabbits (Fig. 5e). Together, these results suggest
that NAbs against the autologous Tier 1A ConM virus do not
target linear V3 epitopes but epitopes on or very near the V1V2
on the trimer apex.
Next, we evaluated the NAb activity of ten rabbit sera against a
panel of ConS virus mutants (Supplementary Table 7). Substitu-
tions Y173A, N301A (removing a glycan), and G324A consis-
tently reduced ConS sensitivity to NAb activity, providing almost
complete resistance against the NAb activity in the five sera from
the trimer-recipient animals, and considerably reducing sensitiv-
ity to the five sera from nanoparticle recipients. The G324A
substitution had the largest effect (up to 30-fold reduction in
sensitivity; Supplementary Table 7). In contrast, a N332A
substitution, removing the glycan at that position, consistently
enhanced NAb sensitivity, although the effect was subtle.
The sera that neutralized the TV1.21 virus, i.e., the sera from
the five nanoparticle recipients, were also tested against a small
panel of TV1.21 mutants (Supplementary Table 7). The K169E
substitution completely abrogated TV1.21 neutralization, while
the N160K and N332A substitutions consistently enhanced
TV1.21 sensitivity to the five sera by approximately two-fold
and four-fold, respectively (Supplementary Table 7). Combined,
these data suggest that the NAb specificities against the ConS and
TV1.21 viruses are directed against conformational epitopes
around the V3 base and apex involving residues 169 and 173 in
V2, residue 324 in V3, and the glycan at position 301 in V3. These
residues are in close proximity to the epitopes for PG9 and
PGT128, in line with the strong serum competition with these
bNAbs (summarized in Fig. 5f). Removal of the glycans at
positions 160 and 332 glycan appears to enhance exposure of this
epitope.
In summary, ConM SOSIP.v7 trimers, especially when
presented on nanoparticles, induce NAbs that target the apex
around the V1V2 and V3 regions on the ConM, ConS, and
TV1.21 viruses, and the sera of most rabbits competed with the
binding of (gl-)bNAbs that target this region, suggesting that
these regions form the immunodominant epitope(s) of ConM
SOSIP.v7 in rabbits.
ConM SOSIP.v7 nanoparticles induce ConS NAbs in maca-
ques. We next evaluated the immunogenicity of ConM SOSIP.v7-
ferritin nanoparticles in rhesus macaques when combined in a
trivalent cocktail with AMC008 SOSIP.v5.2-ferritin and AMC011
SOSIP.v5.2-ferritin nanoparticles5,16,44,53. Six animals received
three intramuscular vaccinations at weeks 0, 4, and 20 of 33 µg of
each nanoparticle construct (i.e., 100 µg nanoparticle protein
mass in total per animal per time point) formulated in AddaVax
adjuvant (Fig. 6a). Two control animals received adjuvant only
and were negative for all specific serological assays throughout the
experiment.
After two immunizations with the nanoparticle cocktail, the
rhesus macaques developed strong binding responses against the
ConM SOSIP.v7 trimer that waned and were then boosted by the
third vaccination (Fig. 6b), which mirrored the results of the
rabbit immunizations (Fig. 4b). Furthermore, all vaccinated
macaques induced specific Ab responses against the ferritin
component. Similar binding Ab responses were also detected in
the rabbits that received ferritin nanoparticles (Supplementary
Fig. 9), indicating that H. pylori ferritin is immunogenic in both
animal models, consistent with previous findings using ferritin
nanoparticles displaying influenza hemagglutinin immunogens54.
The ConM NAb activity measured over time mirrored the
ConM SOSIP.v7-binding responses and peaked at weeks 6 and 22
(Fig. 6c). The sera from all animals that received the nanoparticle
cocktail vaccine neutralized the autologous ConM virus with a
median ID50 of 1880 at week 22. The ConM NAb activity in the
macaque sera was depleted by the autologous trimer but not by
the hybrid trimer containing the BG505 V1V2 domain nor by the
autologous V3 peptide (Fig. 6d), suggesting that the macaque
ConM NAbs targeted epitopes that were shared with the rabbit
NAbs. The related heterologous ConS virus was neutralized by all
six animals, albeit with ~15-fold lower titers compared to the
ConM virus (median ID50 of 123) (Fig. 6e).
Neutralization experiments with the ConS mutant viruses
yielded somewhat different results compared to those obtained
with the rabbit sera. For example, viruses with N332A and T607S
substitutions were neutralized less efficiently by macaque sera,
suggesting that the ConS NAbs in the macaques target somewhat
different epitopes than those in the rabbits and/or that these
epitopes are approached differently (Fig. 6f, Supplementary
Table 9). The sera of the immunized macaques also neutralized
the heterologous Tier 1A SF162 and MW965.26 viruses (median
ID50 values of 837 and 739, respectively), and these NAbs were
partially depleted by the V3 peptide (Fig. 6e, Supplementary
Table 9). The AMC008 and AMC011 nanoparticles in the
cocktail vaccine did not induce autologous NAb responses in
these animals nor did we detect neutralization against hetero-
logous Tier 2 viruses, including TV1.21 (Fig. 6e and Supplemen-
tary Table 8). In summary, ConM SOSIP.v7-ferritin nanoparticles
are able to induce NAbs against the autologous Tier 1A ConM
virus and the related ConS virus in macaques.
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Discussion
We described the design, characterization, crystal structure, and
immunogenicity of ConM SOSIP.v7, a native-like trimer based on
the consensus sequence of HIV-1 group M. ConM SOSIP.v7 can
be purified in high yields, has all of the hallmarks of a properly
folded native-like trimer, and binds to several inferred germline
bNAbs. The crystal structure described here provides a useful
starting point for designing future immunogens. Although we did
not perform a direct comparison with ConM gp120 or nonnative
ConM gp140 forms, the ConM SOSIP.v7 trimer induced very
strong autologous NAb responses against the autologous Tier 1A
ConM virus in animals, especially when presented on ferritin
nanoparticles, and induced substantial NAb responses against the
related ConS virus.
Native-like Env trimers described thus far were based on Env
sequences from single natural virus isolates55–57 with few
exceptions37,58. Here we showed that it is possible to generate stable
native-like Env trimers from an in silico derived, i.e., “non-natural,”
Env sequence. The design of this consensus trimer was facilitated by
combining the original SOSIP.664 mutations4,6,7,59,60 with the more
recent H66R, A316W, I535M, and Q543N substitutions (SOSIP.
v4.216,61,62), the A73C-A561C intersubunit disulfide bond (SOSIP.
v5.25), and additional substitutions described by Guenaga et al.17.
This combination of modifications, here termed SOSIP.v7, might
constitute a general recipe for making native-like trimers from a
given Env sequence, natural or unnatural, and thus a next-
generation SOSIP trimer design platform.
The ConM SOSIP was made to minimize clade-specific or
individual isolate-specific antigenic determinants with the goal of
generating a component of a bNAb-inducing vaccine. Indeed, the
ConM trimer contains less rare surface-exposed residues than
BG505 and thus probably displays less strain-specific antigenic
determinants. Fewer ConM-specific antigenic determinants might
generate less potentially distracting specific Abs and facilitate
driving increased neutralization breadth. By determining the
ConM-specific antigenic determinants, ConM SOSIP.v7 could be
further engineered to reduce ConM-specific rare residues on the
surface while maintaining its overall intact trimeric structure and
antigenicity for bNAbs.
The mapping of the NAb responses point to involvement of
epitopes at or near the V1V2 at the trimer apex. The immuno-
dominant epitope(s) on ConM trimers is/are thus quite different,
compared with those on BG505 SOSIP trimers that often involve
a hole in the glycan shield on trimer stem, and might make the
response to the ConM trimer more amenable for
broadening10,63,64. This notion is supported by the observation
that ConM trimers induce Abs that compete with (gl-)bNAbs
that target the trimer apex. Such apex responses are much less
likely to be induced by previously generated group M consensus
immunogens based on, for example, gp120 or non-native
trimers2,12–15,65, because the trimer apex is likely not appro-
priately presented on these immunogens. Isolation and char-
acterization of monoclonal NAbs from the ConM immunized








































6 16 20 22–4
* *
*




































































































































Fig. 6 Immunogenicity of ConM SOSIP.v7-ferritin in macaques. a Macaque immunization schedule. Macaques were immunized at weeks 0, 4, and 20
(black arrows) and the Ab responses were analyzed at weeks−4, 0, 4, 6, 16, 20, and 22 (gray arrows). b Endpoint antibody-binding titers over time against
ConM SOSIP.v7 trimer as measured by D7324-capture enzyme-linked immunosorbent assay. Mean titers (n= 6 animals) with SD are shown. Values are
from one experiment performed in duplo. c Neutralization titers with over time against ConM virus. Mean titers (n= 6 animals) with SD are shown.
d Neutralization titers against ConM in the presence or absence of ConM SOSIP.v7 D368R, ConM SOSIP.v7 D368R with the V1V2 of BG505, or the ConM
V3 peptide. Statistical analysis was performed using the Wilcoxon matched-pairs signed-rank test; *p < 0.05. e Neutralization titers (ID50) from macaque
sera samples at week 22 against autologous ConM virus (DUMC), heterologous Tier 1 SF162 virus (AMC), and MW965.26 virus (DUMC), and
heterologous ConS and TV1.21 virus (DUMC). Neutralization data from individual animals can be found in Supplementary Table 8. f Relative neutralization
titers of sera against a panel of ConS mutants. Neutralization data from individual animals can be found in Supplementary Table 9. Statistical analysis was
performed by Kruskal–Wallis test and Dunn’s test to correct for multiple testing. **p < 0.01 and ***p < 0.001
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binding of NAbs that target ConM, ConS, and TV1.21 and this
will be crucial to inform future vaccine design improvements.
The induction of NAb responses by ConM SOSIP.v7 trimers
benefited from presentation on ferritin nanoparticles, as the
rabbits in the nanoparticle groups developed enhanced auto-
logous Tier 1A ConM NAb responses, as well as Tier 1B ConS
and Tier 2 TV1.21 responses. The beneficial effects of particulate
antigen presentation through more efficient B cell activation are
well known43,44,54,66,67. Indeed, using calcium flux assays, we
confirmed that ConM SOSIP.v7-ferritin nanoparticles strongly
activated B cells bearing bNAbs PG16, PT145, VRC01, or
PGT121 as the BCR.
There is still, however, room for improvement of the nano-
particle platform. First, the ferritin component induced anti-fer-
ritin Ab responses, which might distract from Env-specific bNAb
responses. A solution could be to immunosilence ferritin by
adding glycans68. Second, the NS-EM and DLS analyses showed
that, in addition to fully assembled particles displaying eight
trimers, incomplete particles were also present. Third, a portion
of the trimers on the nanoparticles was not cleaved at the gp120/
gp41 junction as assessed by SDS-PAGE analysis (Supplementary
Fig. 5b). In general, one-component nanoparticles that assemble
intracellularly, such as ferritin, might be suboptimal because it
will be difficult to ensure that all trimers on each particle are bona
fide native-like trimers. Novel nanoparticle platforms, in parti-
cular two-component nanoparticle systems, in which one can first
purify single native-like trimers and then assemble the nano-
particles post-purification, offer opportunities to do so69.
Following the same overall consensus sequence strategy, one
could pursue a similar approach for generating Env immunogens
that are based on the consensus sequence of the majority circu-
lating sequences in a specific geographical region. Therefore, we
have recently generated Env immunogens using consensus
sequences of clades B, C, and H using the same SOSIP.v7 design
(unpublished), which are currently being explored further and
could be instrumental reagents for regional vaccine strategies.
Rutten et al. have also described a SOSIP trimer based on the
consensus sequence of clade C37. Immunogens based on a con-
sensus sequence could be very useful for other pathogens with
high diversity, such as influenza virus70, Ebola virus, and hepatitis
C virus71. The observation that the consensus sequences can form
properly folded native-like Env proteins in high yield shows that
such strategies are feasible.
Although ConM SOSIP.v7 trimers are unlikely to become
stand-alone immunogens for inducing bNAbs, they may be very
useful in an immunization regimen. For example, they could be
suitable immunogens to boost responses that are primed by a
germline targeting trimer29,38. The ConM trimer is able to bind to
the inferred germline precursors of several bNAbs against the
trimer apex and can induce Abs that compete with these same gl-
bNAbs, which is highly relevant in this context. The low abun-
dance of strain-specific antigenic determinants is an advantage.
Thus, we propose that the ConM SOSIP.v7 trimer is a suitable
component in immunization regimens aimed at inducing bNAbs.
A cGMP stock of ConM SOSIP.v7 has recently been produced
and the protein will be evaluated in phase I clinical trials starting
in 2019.
Methods
Construct design. The ConM env gene is derived from the last published group M
consensus sequence (2004; www.hiv.lanl.gov; alignment ID: 104CP2, Supplemen-
tary Fig. 1), which is a consensus sequence of all of the consensus sequences of each
clade in group M. The ConM SOSIP.v4.2 construct was designed as previously
described4,16. To improve the formation of soluble trimers, the construct contained
the following changes compared to the original ConM env sequence: a TPA signal
sequence, A501C and T605C (gp120-gp41ECTO disulfide bond), I559P in gp41ECTO
(trimer-stabilizing), H66R and A316W (trimer-stabilizing), I535M and Q543N in
gp41ECTO (improved trimerization), REKR to RRRRRR (R6) in gp120 (cleavage
enhancement), and a stop codon after gp41ECTO residue 664. The construct was
codon-optimized, ordered from Genscript (Piscataway, NJ, USA), and cloned into
the pPPI4 plasmid. A second intermolecular disulfide bond was then added by
introducing mutations A73C in gp120 and A561C in gp415, resulting in ConM
SOSIP.v5.2. Addition of TD8 mutations (E47D, N49E, V65K, E106T, I165L,
G429R, and K500R; the sequence already contains a Q at position 432)17 resulted
in ConM SOSIP.v7 (Supplementary Table 1). The interprotomer disulfide bond
that is part of the SOSIP.v6 design was not included in the SOSIP.v7. Point
mutations were made by Quickchange site-directed mutagenesis (Agilent Tech-
nologies, La Jolla, CA, USA) and verified by sequencing. Untagged trimers were
used for experiments described in Figs. 1c and 3f and for all immunizations. In
addition to untagged trimers, we also generated D7324-tagged and His-tagged
trimers4. D7324-tagged constructs were generated by adding the amino acid
sequence GSAPTKAKRRVVQREKR after residue 664 in gp41ECTO. His-tagged
constructs were generated by adding the amino acid sequence
GSGSGGSGHHHHHHHH after residue 664. The GS amino acid sequence
(underlined) in both tags contains a BamHI restriction site. D7324-tagged trimers
were used for experiments described in Figs. 1d–f and 3c and Supplementary
Figs. 2a–d and 5a, while His-tagged trimers were used for the experiments
described in Fig. 1g. The ConM SOSIPv7-ferritin construct was generated by fusing
the N-terminus from H. pylori ferritin (Genbank accession no. NP_223316),
starting from Asp5, to the SOSIP.664 C-terminus, separated by a GSG linker44. The
plasmid containing ferritin only was constructed by replacing the ConM SOSIP.
v7 sequence in the ConM SOSIP.v7-ferritin plasmid with a N-terminal His6-tag
followed by a GGSG-linker.
The IMC of ConM was constructed by using the molecular clone of LAI as
backbone (pLAI)73. This clone contains a unique SalI restriction site 434
nucleotides upstream of the env start codon and a unique BamHI site at the codons
specifying amino acids G751 and S752 in LAI gp160 (HxB2 numbering). A DNA
fragment containing the LAI sequences between the SalI site and the env start
codon, followed by the ConM env sequence up to the BamHI site, was synthesized
and cloned into the LAI molecular clone backbone using SalI and BamHI
(Genscript, Piscataway, NJ). The resulting molecular clone encodes the complete
ConM gp160 sequence, except for the C-terminal 106 amino acids of the
cytoplasmic tail, which are derived from LAI gp160.
Protein expression and purification. Adherent HEK293T cells (ATCC, CRL-
11268) were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) sup-
plemented with 10% fetal calf serum (FCS), penicillin (100 U/mL), and strepto-
mycin (100 µg/mL) and transfected as described previously16. The cell supernatants
containing unpurified SOSIP trimers were harvested 3 days after transfection.
Suspension 293F (Invitrogen, cat no. R79009) and 293S cells (ATCC, CRL-3022)
were maintained in FreeStyle medium (Life Technologies) and co-transfected using
1 mg/mL PEImax (Polysciences Europe GmBH, Eppelheim, Germany) at a density
of 0.8–1.2 million cells/mL with a plasmid expressing SOSIP and a plasmid
encoding furin in a 4:1 ratio to ensure gp140 cleavage or 1:1 when expressing
ConM SOSIP.v7-ferritin nanoparticles44. The supernatant was harvested 7 days
after transfection, centrifuged, and filtered using Steritops (0.22 µm pore size;
Millipore, Amsterdam, The Netherlands) before further use. SOSIP trimers were
purified essentially as previously described16,72. In brief, filtered supernatant from
293F or 293S cells was flowed (0.5–1.0 mL/min) over a PGT145 or 2G12 affinity
column, prepared as previously described72, at 4 °C. 2G12 purification was followed
by SEC. Protein concentrations were determined with Nanodrop (Thermo Scien-
tific, Wilmington DE, USA) using theoretical molecular weight and extinction
coefficient calculated with Expasy (ProtParam tool).
The ConM SOSIP.v7-ferritin nanoparticles were purified by adding the CNBr-
activated sepharose 4B beads (GE Healthcare) carrying PGT145 to the filtered
supernatant and incubated on a roller at 4 °C overnight. Subsequently, the
supernatant and beads were passed over an Econo-Column chromatography
column (Biorad). The column was then washed with three column volumes of 0.5
M NaCl and 20 mM Tris HCl pH 8.0. Protein was eluted with 3.0 M MgCl2 pH 7.5
and immediately buffer exchanged into TN75 buffer (75 mM NaCl, 20 mM Tris
HCl pH 8.0) using a 100-kDa cut-off Vivaspin20 filter (Sartorius, Gӧttingen,
Germany).
For crystallography, the PGT124 and 35O22 Fabs were overexpressed by
transient transfection in the FreeStyle 293F cells for 5 days and purified by
affinity chromatography using CaptureSelect LC lambda (Thermo Fisher
Scientific), cation exchange chromatography, and SEC with Superdex200 16/60
column (GE Healthcare). The ConM SOSIP.v7 construct was cloned into a
phCMV3 vector and overexpressed in FreeStyle 293S cells for 6 days and purified
by 2G12-affinity chromatography, followed by SEC. The purity of all trimers and
Fabs was assessed using SDS-PAGE and Blue Native-PAGE (BN-PAGE),
followed by Coomassie blue staining as previously described4. The His6-tagged
ferritin nanoparticles (without Env trimers) were expressed in FreeStyle 293F
cells and purified by gravity flow over a Ni-NTA column (Qiagen) followed by
SEC over a Superdex200 10/300 GL increase column. Fractions corresponding to
the size of the ferritin 24-mer were pooled and concentrated in phosphate-
buffered saline (PBS).
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SDS-PAGE and BN-PAGE. SOSIP trimers were analyzed using SDS-PAGE and
BN-PAGE followed by western blotting or Coomassie blue staining as described
previously16.
Enzyme-linked immunosorbent assay. For D7324-capture ELISA, supernatants
from HEK293T cells containing unpurified SOSIP trimers, or PGT145-purified
SOSIP trimers (1.0 µg/mL), were diluted in Tris-buffered saline (TBS). The trimers
were then immobilized via their D7324-tags for 2 h at room temperature on half-
well 96-well plates (Greiner) precoated with Ab D7324 (Aalto Bioreagents) at 10
µg/mL in 0.1 M NaHCO3 pH 8.6 overnight4,50. Midpoint and end point antibody
titers from sera samples were determined in D7324-capture ELISA as previously
described3. For lectin-capture ELISA, half-well 96-well plates were coated with
Galanthus nivalis lectin (Vector Laboratories) at 20 µg/mL in 0.1 M NaHCO3 pH
8.6 overnight, which were then blocked using Casein Blocker (Thermo Scientific)
followed by immobilization of the purified SOSIP trimer and SOSIP-ferritin pro-
teins in TBS (2.0 µg/mL). Subsequent steps were performed as previously descri-
bed4. For Ni-NTA His-capture ELISA, the purified SOSIP trimers (1.0 µg/mL) were
diluted in TBS and immobilized on 96-well Ni-NTA ELISA plates (Qiagen).
Subsequent steps were performed identical to the D7324-capture ELISA. For the
ELISA in Supplementary Fig. 9, 2 µg/mL of purified ferritin cages were coated
overnight on half-well 96-well plates, which were then blocked using Casein
Blocker. Subsequent steps were performed as described above.
Competition ELISA. For bNAb competition ELISA experiments, rabbit sera (1:100
dilution) were incubated for 30 min with D7324-tagged ConM SOSIP.v7 that was
captured onto solid phase using a D7324 tag. Human bNAbs were then added at a
concentration to give sufficient signal (optical density 0.8–2.0) without competitor
(0.1 μg/mL for PGT121, PGT128, and PGT135; 0.2 μg/mL for VRC01, VRC26.25,
and PG16; 0.6 μg/mL for PG9 and PGT145; 1.0 μg/mL for 3BC315 and 35O22; 5.0
μg/mL for CH01 and gl-PG9; 10 μg/mL for gl-CH01). The bound bNAb was
detected using horseradish peroxidase-labeled donkey anti-human IgG conjugate
that was minimally cross-reactive with rabbit IgG (Jackson Immunoresearch,
Westgrove, PA). The remaining binding signal of each well was subtracted from the
negative control that contained serum but no bNAb (set to 0%) and compared to
binding signal of the wells with bNAb only (set to 100%)3.
BLI and thermostability assay. ConM SOSIP.v7 trimer or ConM SOSIP.v7-fer-
ritin (1000 nM equimolar Env in PBS) were incubated for 1 h at 4 °C, 37 °C, 60 °C,
68 °C, or 72 °C. After 1 h, samples were diluted to 100 nM in BLI running buffer
(PBS/0.1% bovine serum albumin/0.02% Tween20) and antibody binding was
assessed using a ForteBio Octet K2. The binding assays were performed at 30 °C
and with agitation set at 1000 rpm. Antibody was loaded on protein A sensors
(ForteBio) at 2.0 μg/mL in running buffer until a binding threshold of 0.5 nm was
reached. Association and dissociation were measured for 300 s. Binding to a pro-
tein A sensor not loaded by antibody was set as background.
Negative-stain electron microscopy. SOSIP trimers were imaged and processed
as described previously16. In short, a 3-µL aliquot containing ∼0.03 mg/mL of
trimer or nanoparticles were applied for 5 s onto a carbon-coated 400 Cu mesh grid
that had been glow discharged at 20 mA for 30 s, then negatively stained with 2%
(w/v) uranyl formate for 60 s. Data were collected on a FEI Tecnai T12 electron
microscope operating at 120 keV.
Differential scanning calorimetry. Thermal denaturation was studied using a
nano-DSC calorimeter (TA instruments, Etten-Leur, The Netherlands)16. In short,
ConM SOSIP.v7 trimer or ConM SOSIP.v7-ferritin were first dialyzed against PBS,
and concentration was then adjusted to ~0.25 or ~1.0 mg/mL, respectively. After
loading the sample into the cell, thermal denaturation was probed at a scan rate of
60 °C/h. Buffer correction, normalization, and baseline subtraction procedures
were applied before the data were analyzed using the NanoAnalyze Software v.3.3.0
(TA Instruments). The data were fitted using a non-two-state model, as the
asymmetry of some of the peaks suggested that unfolding intermediates were
present. DSC experiments were performed with a D7324-tagged trimer, but the
presence of the D7324-tag did not alter the Tm values compared to the corre-
sponding non-tagged trimers16.
Dynamic light scattering (DLS). DLS measurements were performed at 20 °C
using a Dynapro Nanostar instrument (Wyatt Technologies), with 10 acquisitions
of 5 s each. Each sample was centrifuged at 10,000 × g for 10 min prior to the DLS
measurements to remove any trace of aggregates or dust from the sample. The
hydrodynamic radii (Rh) were calculated using the Dynamics Analysis software
(Wyatt Technologies), assuming a spherical model.
Glycan profiling (hydrophilic interaction liquid chromatography-ultra perfor-
mance liquid chromatography (HILIC-UPLC)). Glycan profiling was done as
previously described18. In short, SOSIP trimers were resolved by SDS-PAGE. Bands
corresponding to gp140 were excised and the N-linked glycans attached to gp140
protein were released by N-glycosidase F (PNGase F; NEB). Glycans were labeled
with 2-aminobenzoic acid. Fluorescently labeled glycans were resolved by HILIC-
UPLC using a 2.1 × 10 mm2 Acquity BEH Amide Column (1.7 μm particle size)
(Waters, Elstree, UK). Fluorescence was measured using an excitation wavelength
of 250 nm and a detection wavelength of 428 nm. Data processing was performed
using the Empower 3 software (Waters Corporation, Milford, MA, USA). The
percentage abundance of oligomannose-type glycans was calculated by integration
of the relevant peak areas before and after Endoglycosidase H (EndoH) digestion,
following normalization.
Crystallization and data collection. For complex formation, ConM SOSIP.v7
trimers, Fab PGT124, and Fab 35O222 were mixed in a 1:3.2:3.2 molar ratio and
treated with EndoH (New England Biolabs) in 200 mM NaCl and 50 mM sodium
citrate pH 5.5 for 45 min at 37 °C to decrease the heterogeneity of trimer:antibody
complexes31,32, followed by further SEC purification. SEC-purified ternary com-
plexes were concentrated to ∼6 mg/mL and screened against 480 crystallization
conditions at 22 °C and 4 °C using our robotic CrystalMation system (Rigaku) at
TSRI. Initial crystals of ConM SOSIP.v7 in complex with Fabs PGT124 and 35O22
were grown in JCSG Core II Suite (QIAGEN) condition G6 (0.07 M sodium
acetate, 30% (v/v) glycerol, 5.6% (w/v) PEG 4000, pH 4.6), and after further
optimization, crystals for data collection were obtained in 0.07 M sodium acetate,
30% (v/v) glycerol, and 6% (w/v) PEG 4000, pH 3.93. Crystals were flash cooled in
liquid nitrogen since the crystallization condition already included a cryoprotec-
tant. Diffraction data were collected at Advanced Photon Source beamline 23-ID-D
and integrated/scaled with HKL-2000 to 3.9 Å in space group P63 with unit cell
parameters a= b= 127.6 Å, c= 315.5 Å (Table 2).
Structure determination and refinement. The ternary complex structure was
solved by molecular replacement method with Phaser74 using the crystal structure
of BG505 SOSIP.664 in complex with Fabs 3H+109L and 35O22 (PDB ID: 5CEZ)
as a phasing model. After inserting the amino acid substitutions present in ConM
SOSIP.v7 and PGT124, the initial structure was refined, using the LORESTR
pipeline75, and model building was performed using Coot76 and refined with
Refmac577. The final Rwork and Rfree values were 24.7% and 29.6%, respectively, and
residues in the Ramachandran favored and outliers region were 96.1% and 0.4%,
respectively (Table 2). The Fab residues were numbered according to Kabat et al.78
and gp120-gp41 residues using HxB2 numbering. Ramachandran statistics were
calculated with MolProbity79.
B cell activation. WEHI-231 B cell lines expressing the specific bNAbs (VRC01,
PGT145, PGT121, and PG16) were donated by Takayuki Ota and David Nemazee
at The Scripps Research Institute and were maintained in advanced Dulbecco’s
Modified Eagle’s Medium (DMEM) supplemented with 10% FCS, β-mercapto-
ethanol (55 µM), L-glutaMAX (2mM), penicillin (100 U/mL), and streptomycin
(100 µg/mL) (advanced DMEM++). The activation experiments and calcium flux
measurements were performed as described elsewhere26,47. In short, 1 day prior to
the assay, cells were incubated with 1 µg/mL doxycycline to induce the expression
of BCRs. The next day, cells were suspended at 4 million cells/mL in advanced
DMEM++, labeled with 1.5 µM Indo-1 (Invitrogen) for 30 min at 37 °C and
washed with HBSS (Hank’s Balance Salt Solution) containing 2 mM CaCl2, fol-
lowed by another incubation of 30 min at 37 °C. Aliquots of 1 million cells/mL
were then stimulated at room temperature with SOSIP trimers, nanoparticles, or
control reagents. Calcium (Ca2+) signals were recorded on a LSR Fortessa (BD
Biosciences) by measuring for 210 s the 405/485 nm emission ratio of Indo-1
fluorescence upon UV excitation. ConM SOSIP.v7 and ConM SOSIP.v7-feritin
were tested at concentrations of 50 nM Env equivalent, i.e., 6.25 nM of ferritin
nanoparticles. Kinetic analyses were performed using FlowJo v10.
Immunizations. In a first immunization study, 10 rabbits (New Zealand White,
female, 2 groups, 5 animals/group) were immunized under subcontract at Covance
(Denver, USA) with either 22 µg (Env protein content only; i.e., glycans are ignored
in recording amounts) of PGT145-purified ConM SOSIP.v7 or ConM SOSIP.v7-
ferritin formulated in 75 units of ISCOMATRIX™ adjuvant (CSL Ltd., Parkville,
VIC, Australia) by two intramuscular immunizations in each quadriceps at weeks
0, 4, and 20. All immunization procedures complied with all relevant ethical reg-
ulations and protocols of the Covance Institutional Animal Care and Use Com-
mittee (IACUC). In a second study, 12 other rabbits (New Zealand White, female, 6
animals/group), at the Central National Food Chain Safety Office, Directorate of
Veterinary Medicinal Products (NFCSO-DVMP, Gödölló, Hungary), received
either 20 µg of PGT145-purified ConM SOSIP.v7 or ConM SOSIP.v7-ferritin
formulated inSE (Polymun, Klosterneuburg, Austria) by two intramuscular
immunizations in each quadriceps at weeks 0, 4, and 20. Antigen was mixed 1:1
with SE (i.e., 250 µL of antigen in PBS combined with 250 µL SE). All procedures
complied with all relevant ethical regulations for animal testing of the animal ethics
committee of NFCSO-DVMP.
Rhesus macaques (Macaca mulatta, female, 1 group, 6 animals) received a
PGT145-purified SOSIP-ferritin mix (trivalent cocktail with ConM SOSIP.v7-
ferritin, AMC008 SOSIP.v5.2-ferritin and AMC011 SOSIP.v5.2-ferritin; 33 µg
protein mass each) formulated in adjuvant (AddaVax, InvivoGen, San Diego, USA)
by three intramuscular immunization (left arm, right arm, left thigh) at weeks 0, 4,
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and 20. Two control macaques received adjuvant only. Macaque immunizations
were carried out at the Biomedical Primate Research Centre (BPRC, Rijswijk, The
Netherlands). All procedures and protocols complied with all relevant ethical
regulations for animal testing of BPRC’s Animal Experiments Committee.
Neutralization assay. TZM-bl and U87 neutralization assays were performed
essentially as described elsewhere80. The assays were performed at four different
sites: AMC, Academic Medical Center, Amsterdam, The Netherlands; DUMC,
Duke University Medical Center, Durham, NC, USA; OSR, San Raffaele Scientific
Institute, Milan, Italy; and ISCIII, Instituto de Salud Carlos III, Madrid, Spain. The
TZM-bl reporter and U87 cell line were obtained through the NIH AIDS Research
and Reference Reagents Program, Division of AIDS, NIAID, NIH (John C. Kappes,
Xiaoyun Wu and Tranzyme Inc., Durham, NC, USA and HongKui Deng and Dan
R. Littman, respectively). The ID50 values were determined as the sera dilution at
which infectivity was inhibited by 50%.
To determine the specificity of the NAb responses against ConM, sera were first
incubated for 1 h at room temperature with 40 µg/mL of a depletion reagent.
Subsequent steps of the neutralization assay were performed as described. ConM
and BG505 have identical V3 sequences and the V3 peptide depletion reagent was
as described before (TRPNNNTRKSIRIGPQAFYATGDIIGDIRQAH)3. The ConM
SOSIP.v7 trimer with the swapped V1V2 was constructed by replacing the V1V2 of
ConM (residues 131–196 in HXB2 numbering) with that of BG5054. All ConM
SOSIP.v7 depletion reagents contain the D368R mutation to abrogate binding to
CD4 on the TZM-bl receptor cell line and were positively selected by PGT145
affinity chromatography to ensure that only native-like trimers were used in the
depletion experiments.
HIV-1 Env amino acid conservation. We used 6112 HIV-1 Env protein sequences
from the Los Alamos HIV database (http://www.hiv.lanl.gov/) as present in 2017 to
determine amino acid frequencies of HIV-1 Env residues. All HIV-1 Env protein
sequences were aligned with the Jalview program and amino acid propensities per
residue were calculated according to the alignment result from Jalview with 6112
Env protein sequences.
Statistical analyses. Groups were compared using unpaired two-tailed
Mann–Whitney U test unless noted otherwise. Spearman’s rank correlation coef-
ficient was used to determine correlations. All statistical analyses were performed
in Graphpad Prism 7.0.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The coordinates and structure factors for the ConM SOSIP.v7 structure in complex with
Fab PGT124 and Fab 35O22 have been deposited in the Protein Data Bank (PDB code
6IEQ). All other data supporting the findings in this manuscript are available from the
corresponding authors (R.W.S., B.W.H., and I.A.W.) upon reasonable request.
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